Comparative Pharmacology
Head-to-head clinical analysis: PROTONIX versus ZEGERID OTC.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PROTONIX versus ZEGERID OTC.
PROTONIX vs ZEGERID OTC
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Proton pump inhibitor that inhibits the H+/K+-ATPase enzyme system at the secretory surface of gastric parietal cells, blocking the final step of gastric acid secretion.
Omeprazole is a proton pump inhibitor (PPI) that suppresses gastric acid secretion by irreversibly binding to the H+/K+-ATPase enzyme (the proton pump) in the gastric parietal cells.
40 mg orally once daily; alternatively, 40 mg IV once daily for 7-10 days.
20 mg orally once daily before a meal for 14 days for frequent heartburn; 20 mg orally once daily for up to 8 weeks for erosive esophagitis healing; 20 mg orally once daily for maintenance of healed erosive esophagitis (up to 12 months).
None Documented
None Documented
Terminal elimination half-life is about 1–2 hours in healthy individuals; in CYP2C19 poor metabolizers or hepatic impairment, half-life may increase up to 3–6 hours, but clinical impact is minimal due to irreversible binding to H+/K+-ATPase.
Terminal half-life approximately 1.5-2 hours (0.5-1 hour in children); due to short half-life, acid suppression duration is prolonged via irreversible proton pump inhibition
Approximately 80% of a dose is excreted as metabolites in urine, with the remainder (≈20%) in feces via biliary elimination.
Renal (80% as metabolites) and fecal (20%)
Category C
Category C
Proton Pump Inhibitor
Proton Pump Inhibitor